. These methodological limitations and the fragmentation of publication of the available data on various thrombophilias and outcomes, has made it difficult for clinicians to obtain a clear overview of the overall risks of VTE and adverse pregnancy outcomes in women with thrombophilia. Thus a comprehensive review of the risk of heritable and acquired thrombophilias in pregnancy is required. The objective of this study was to assess the overall relationship between all major thrombophilias and VTE and the adverse outcomes of pregnancy loss, pre-eclampsia, IUGR and abruption. Furthermore the available data on prophylactic intervention in this situation were also evaluated. . Relevant keywords relating to thrombophilia, VTE and adverse pregnancy outcomes were combined with established search filters for randomised controlled trials and observational studies (NHS Centre for Review & Dissemination, 2001 ) to capture all potentially relevant studies. Only articles published in English were retrieved. In addition, hand searching the abstracts of recent thrombosis conferences and the references of all studies meeting the reference criteria were also carried out.
Methods

Searching
Inclusion and exclusion criteria
Studies were included in the review if they met the following criteria: (i) study population included women with one or more identified thrombophilia who were pregnant or up to 6-week postpartum; (ii) clinical outcomes included incidence of VTE events and/or adverse pregnancy outcomes were recorded; (iii) extractable data that defined categorically the presence or absence of any thrombophilic defects were available; and (iv) study design described as randomised controlled trials, prospective observational studies or retrospective observational studies. Studies with cases selected on the basis of autoimmune disease, studies without controls or with control groups that included men or current users of hormonal contraceptives were excluded.
Data abstraction and quality assessment
Data extraction was carried out independently by two investigators using pre-piloted data extraction forms, and the quality of the studies was also assessed. Major study outcomes included all VTE and adverse pregnancy incidences. Venous thromboembolism events included all objectively diagnosed DVT and PE events. Adverse pregnancy outcomes including early pregnancy loss (spontaneous loss in the first or second trimester), late pregnancy loss (spontaneous loss in the third trimester), pre-eclampsia (diastolic blood pressure ‡90 mmHg plus proteinuria; Walker, 2000b) , placental abruption, IUGR (birth weight below the 10th centile for gestational age), and postpartum haemorrhage (defined as minor if blood loss was 500-1500 ml and major if blood loss was >1500 ml after childbirth) (Scottish Obstetric Guidelines and Audit Project, 1998) .
To evaluate the effectiveness of prophylactic interventions in pregnant women with thrombophilia in the prevention of recurrent pregnancy loss, all the data relating to pharmacological and non-pharmacological prophylactic interventions were extracted for analysis. These include: unfractionated heparin, low molecular weight (LMW) heparins, warfarin, aspirin, dextran, recombinant hirudin, plaquinil, calf compression, foot pumps and compression stockings. In addition, data on adverse drug reactions including haemorrhage, serious wound complications, thrombocytopenia and osteoporotic fractures were also extracted if available.
This review has been designed to summarise clinical evidence across study types, therefore, a single checklist, adapted from quality checklists recommended by the Centre for Review and Dissemination was used (NHS Centre for Review & Dissemination, 2001) . Seven major criteria were assessed including representative inception cohort, appropriate comparator group, blinded assessment of outcomes, adjustment for confounding, appropriate follow-up and description of cohorts. Any disagreement between the reviewers was resolved by discussion.
Analysis
Odds ratios (ORs) for each clinical outcome per woman were calculated and stratified by individual thrombophilic defects. For the purpose of our review, data relating to the first and second trimester losses were aggregated to determine the overall risk of early pregnancy loss, as some publications did not provide data on the gestation at loss. Where possible, the risks of recurrent first trimester and non-recurrent second trimester loss were calculated separately. In addition, the risk of recurrent pregnancy loss was also summarised according to the use of prophylactic interventions to determine the relative effectiveness of different interventions.
Where appropriate, meta-analysis was carried out and pooled OR were calculated based on the random effects model (DerSimonian & Laird, 1986) , which accounts for interstudy variation and provides a more conservative effect than the fixed effect model (NHS Centre for Review & Dissemination, 2001) . Potential sources of heterogeneity were assessed using the standard chi-square test. In addition, the statistic I 2 was used to investigate heterogeneity by examining the extent of inconsistency across the study results (Higgins et al, 2003) . Sensitivity analysis was carried out to assess the robustness of the results of the metaanalysis. Where heterogeneity was present between the studies, differences in study design were examined. All analyses were performed using RevMan 4.1 (Cochrane Collaboration, Oxford, UK).
Results
Of the 234 studies located through electronic databases and hand searching, 79 studies met the inclusion criteria (Fig 1) (63 case control studies, 13 cohort studies and three randomised controlled trials). Data relating to VTE and adverse pregnancy outcomes were extracted for analysis, but no studies reported incidents of postpartum haemorrhage. Overall, the methodological quality of the studies were sound; however, the major limitation common to most studies was the failure to identify additional risk factors in the populations studied (Table I) .
VTE
Nine studies (n ¼ 2526) assessed the risk of VTE in pregnant women with heritable thrombophilia (Grandone et al, 1998; Dilley et al, 2000; Gerhardt et al, 2000; Murphy et al, 2000; Pabinger et al, 2000; Martinelli et al, 2001a Martinelli et al, , 2002 Tormene et al, 2001; Ogunyemi et al, 2003) . With the exception of homozygosity for MTHFR C677T, all heritable thrombophilias were found to be significantly associated with an increased risk of VTE (Fig 2) . In particular, the OR for VTE among factor V Leiden homozygous carriers during pregnancy was as high as 34AE40 (95% CI 9AE86-120AE05) (Gerhardt et al, 2000; Murphy et al, 2000; Martinelli et al, 2001a; Tormene et al, 2001) . The pooled data on MTHFR homozygous cases indicated significant heterogeneity (Fig 2) . However, women in one of the studies were given folic acid supplement, which has potential confounding effects on homocysteine levels and VTE events (Ogunyemi et al, 2003) . This study was excluded when performing the sensitivity analysis. The remaining studies consisted of two retrospec tive case-control (Grandone et al, 1998; Dilley et al, 2000) and one prospective cohort (Murphy et al, 2000) studies. Meta-analysis of the case-control studies only, indicated no significant heterogeneity (P ¼ 0AE49) or inconsistency (I 2 ¼ 0%) and gave an OR of 1AE83 (95% CI 0AE95-3AE51).
Early pregnancy loss
Twenty-five studies (n ¼ 7167) evaluated the association between thrombophilia and early pregnancy loss (Das et al, 1991; Infante-Rivard et al, 1991; Wouters et al, 1993; De Carolis et al, 1994; Ogasawara et al, 1996; Balasch et al, 1997; Grandone et al, 1997a; Nelen et al, 1997; Higashino et al, 1998; Chakrabarti et al, 1999; Hatzis et al, 1999; Holmes et al, 1999; Lissak et al, 1999; Tal et al, 1999; Fatini et al, 2000; Kupferminc et al, 2000a; Pabinger et al, 2000; Younis et al, 2000; Pickering et al, 2001; Pihusch et al, 2001; Rai et al, 2001; Raziel et al, 2001; Reznikoff-Etievan et al, 2001; Carp et al, 2002; Finan et al, 2002) , and showed positive associations overall (Fig 3) . In particular, significantly associations were observed in carriers of homozygous factor V Leiden (OR 2AE71; 95% CI 1AE32-5AE58), heterozygous factor V Leiden (OR 1AE68; 95% CI 1AE09-2AE58), prothrombin heterozygosity (OR 2AE49; 95% CI 1AE24-5AE00), anticardiolipin antibodies (OR 3AE40; 95% CI 1AE33-8AE68), lupus anticoagulants (OR 2AE97; 95% CI 1AE03-8AE56), acquired APCR (OR 4AE04; 95% CI 1AE67-9AE76) and hyperhomocysteinaemia (OR 6AE25; 95% CI 1AE37-28AE42) (Fig 3) . Significant heterogeneity (P ¼ 0AE04) and inconsistency (I 2 ¼ 59AE1%) was observed with the metaanalysis of lupus anticoagulants; however, this could not be explained by study design, as all the studies were case-control studies.
Early pregnancy loss was separated into recurrent pregnancy loss in the first trimester and single pregnancy loss in the second trimester and analysed (Figs 4 and 5) . Due to the limitations of the available data, the analysis on factor V Leiden incorporates both homozygous and heterozygous carriers. These women were found to be at higher risk of pregnancy loss in the second compared with the first trimester (OR 4AE12; 95% CI 1AE93-8AE81 and OR 1AE91; 95% CI 1AE01-3AE61 respectively) (Grandone et al, 1997a; Tal et al, 1999; Tormene et al, 1999; Foka et al, 2000; 2001; Reznikoff-Etievan et al, 2001; Carp et al, 2002; Finan et al, 2002) . However, there was evidence of heterogeneity in the analysis of recurrent first trimester loss (P ¼ 0AE001); this could not be explained by the difference in study design. A similar trend was observed with prothrombin heterozygosity. The risk of non-recurrent second trimester loss (OR 8AE60; 95% CI 2AE18-33AE95) compared with recurrent first trimester loss (OR 2AE70; 95% CI 1AE37-5AE35) was over threefold (Foka et al, 2000; Kupferminc et al, 2000a; Pickering et al, 2001; Pihusch et al, 2001; Reznikoff-Etievan et al, 2001; Carp et al, 2002; Finan et al, 2002) (Figs 4 and 5) . In contrast, acquired activated protein C resistance was associated with a higher risk of recurrent pregnancy loss in the first trimester (OR 2AE60; 95% CI 1AE21-5AE59) than nonrecurrent loss in the second trimester (OR 1AE59; 95% CI 0AE19-13AE44) (Tal et al, 1999; Rai et al, 2001) . However, the calculated risk relating to non-recurrent second trimester loss was non-significant and was based on data from only one study.
Late pregnancy loss
Data relating to late pregnancy loss were extracted from 15 studies (n ¼ 4038) (Infante-Rivard et al, 1991; Bocciolone et al, 1994; De Carolis et al, 1994; Yasuda et al, 1995; Gris et al, 1999; Meinardi et al, 1999; Rothbart et al, 1999; Bare et al, 2000; Kupferminc et al, 2000a; Martinelli et al, 2000; Pabinger et al, 2000; Alfirevic et al, 2001; Agorastos et al, 2002; Alonso et al, 2002; Many et al, 2002) ; significant associations were observed in carriers of heterozygous factor V Leiden (OR 2AE06; 95% CI 1AE10-3AE86), heterozygous prothrombin (OR 2AE66; 95% CI 1AE28-5AE53), protein S deficiency (OR 20AE09; 95% CI 3AE70-109AE15) and anticardiolipin antibodies (OR 3AE30; 95% CI 1AE62-6AE70) (Fig 6) . No evidence of heterogeneity was observed. 
Pre-eclampsia
Twenty-five studies (n ¼ 11 183) assessed the risk of preeclampsia in pregnancy women with thrombophilia (Yasuda et al, 1995; Allen et al, 1996; Dizon-Townson et al, 1996; Grandone et al, 1997b Grandone et al, , 1999 Nagy et al, 1998; Schjetlein et al, 1998; de Groot et al, 1999; Kupferminc et al, 1999 Kupferminc et al, , 2000a Mello et al, 1999; O'Shaughnessy et al, 1999; Van Pampus et al, 1999; Murphy et al, 2000; Rigo et al, 2000; Alfirevic et al, 2001; Dreyfus et al, 2001; Kim et al, 2001; Raijmakers et al, 2001; Agorastos et al, 2002; Benedetto et al, 2002; Currie et al, 2002; D'Elia et al, 2002; Morrison et al, 2002) . The risk of pre-eclampsia was significantly associated with heterozygous factor V Leiden (OR 2AE19; 95% CI 1AE46-3AE27), heterozygous prothrombin (OR 2AE54; 95% CI 1AE52-4AE23), MTHFR homozygosity (OR 1AE37; 95% CI 1AE07-1AE76), anticardiolipin antibodies (OR 2AE73; 95% CI 1AE65-4AE51) and hyperhomocysteinaemia (OR 3AE49; 95% CI 1AE21-10AE11) (Fig 7) . Evidence of * Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia. ** For the Factor V Leiden mutation, homozygous and heterozygous carriers were grouped together as it was not possible to extract data for each state.
Fig 4.
Risk of recurrent first trimester pregnancy loss with thrombophilia. The square on each line represents the point estimate for the odds ratio for each single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence interval from pooling all the studies together in the meta-analysis. heterogeneity was present in the analysis on heterozygous factor V Leiden (P ¼ 0AE04). The studies included in the analysis consisted of diagnoses of both mild and severe preeclampsia. Sensitivity analysis was performed by analysing the studies reporting mild and severe pre-eclampsia independently. When restricting the analysis to mild pre-eclampsia only (Grandone et al, 1997b (Grandone et al, , 1999 Nagy et al, 1998; de Groot et al, 1999; Mello et al, 1999; O'Shaughnessy et al, 1999; Rigo et al, 2000; Kim et al, 2001; Benedetto et al, 2002; D'Elia et al, 2002; ) , an OR of 2AE30 (95% CI 1AE27-4AE16) was obtained, but heterogeneity remained (P ¼ 0AE01). However, when restricting the analysis to severe pre-eclampsia only (Dizon-Townson et al, 1996; Nagy et al, 1998; de Groot et al, 1999; Van Pampus et al, 1999; Alfirevic et al, 2001) , an OR of 2AE04 (95% CI 1AE23-3AE36) was obtained and evidence of heterogeneity was removed (P ¼ 0AE31).
Placental abruption
Seven studies (n ¼ 922) evaluated the association between thrombophilia and placental abruption (Goddijn-Wessel et al, 1996; Owen et al, 1997; Wiener-Megnagi et al, 1998; Kupferminc et al, 1999 Kupferminc et al, , 2000a Alfirevic et al, 2001; Agorastos et al, 2002) . Overall, thrombophilia was associated with an increased risk of placental abruption, but significant associations were only observed with heterozygous factor V Leiden (OR 4AE70; 95% CI 1AE13-19AE59) and heterozygous prothrombin (OR 7AE71; 95% CI 3AE01-19AE76) (Fig 8) .
IUGR
Five studies (n ¼ 195) were included in the analysis of IUGR (Yasuda et al, 1995; Martinelli et al, 2001b; Agorastos et al, 2002; Infante-Rivard et al, 2002; Kupferminc et al, 2002) . There was a general trend of increased IUGR risk in pregnant women with thrombophilia; however, based on data from one study (Yasuda et al, 1995) , significant association was observed only with anticardiolipin antibodies (OR 6AE91; 95% CI 2AE70-17AE68) (Fig 9) .
Prophylactic interventions
Eight studies (n ¼ 619) evaluated the effectiveness of prophylactic interventions in pregnant women with thrombophilia (Kutteh, 1996; Kutteh & Ermel, 1996; Rai et al, 1997; Pattison et al, 2000; Pauzner et al, 2001; Farquharson et al, 2002; Franklin & Kutteh, 2002; Gris et al, 2004) . No data on the prevention of VTE events were found. Four of the studies assessed the effectiveness of heparin plus aspirin versus aspirin alone for recurrent pregnancy loss associated with antiphospholipids (Kutteh, 1996; Rai et al, 1997; Farquharson et al, 2002; Franklin & Kutteh, 2002) . A pooled OR of 1AE62 (95% CI * Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia. ** For the Factor V Leiden mutation, homozygous and heterozygous carriers were grouped together as it was not possible to extract data for each state. * Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
Fig 6. Risk of late pregnancy loss per woman with thrombophilia. FVL, factor V Leiden; PTM, prothrombin; PC, protein C; PS, protein S; ACL, anticardiolipin antibodies; LA, lupus anticoagulant. The square on each line represents the point estimate for the odds ratio for each single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence interval from pooling all the studies together in the meta-analysis. 0AE51-5AE10) was estimated in favour of low-dose aspirin plus heparin in preventing recurrent pregnancy loss. However, minor bleeding (including haematuria, nosebleeds, gum bleeds and bleeding at the injection site) occurred in two of the studies and a pooled OR of 1AE68 (95% CI 0AE38-7AE39) was estimated in favour of low-dose aspirin alone (Kutteh, 1996; Rai et al, 1997) .
In one study, low-dose aspirin and LMW heparin were compared in women with a single unexplained fetal loss from the 10th week of pregnancy (Gris et al, 2004) . Patients treated with LMW heparin were more likely to have a healthy live birth (OR, 15AE5; 95% CI 7AE0-34AE0). Small for gestational age infants were more frequent in patients treated with low-dose aspirin. No other side effects of the treatment were evident in either patients or newborns. Other studies compared the effectiveness of low-dose aspirin versus a placebo (Pattison et al, 2000) , lowdose and high-dose heparin (Kutteh & Ermel, 1996) , and warfarin and heparin (Pauzner et al, 2001) . Therefore, as the prophylactic therapies in these studies are not comparable, the results could not be combined in a meta-analysis.
Discussion
This is the first systematic review to present the overall relationship between all major thrombophilias and VTE and the adverse outcomes of pregnancy loss, pre-eclampsia, IUGR and abruption. These data show that both heritable and acquired thrombophilias are associated with VTE and adverse pregnancy outcomes, so confirming and extending results from previous systematic reviews, which have examined particular aspects of these associations (Gates, 2000; Greer, 2003; Rey et al, 2003) .
Venous thromboembolism was significantly associated with all heritable thrombophilias except in women homozygous for MTHFR C677T, where in contrast to the non-pregnant situation, there was no elevation in risk. The mechanism underlying this lack of association in pregnancy is unclear. It is possible that folic acid supplements taken in pregnancy could reduce homocysteine levels in these women and so reduce the risk of VTE, but there is minimal data on the use of vitamin supplements in the studies reported and this possibility could not be examined with the available data. The risk of VTE with homozygous factor V Leiden was the highest risk observed for any thrombophilia, with a relative risk of 34AE4 (95% CI 9AE86-120AE05), reducing to 8AE32 (95% CI 5AE44-12AE70) with heterozygous factor V Leiden. While these are significant increases in relative risk, the absolute risk remains modest. For example, the underlying incidence of VTE in pregnancy is considered to be around 1:1000. Thus, these relative risks translate to absolute risks of 3AE4% and 0AE8% respectively. Of note, women Risk of pre-eclampsia in women with thrombophilia. The square on each line represents the point estimate for the odds ratio for each single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence interval from pooling all the studies together in the meta-analysis.
heterozygous for factor V Leiden and homozygous for prothrombin G20201A were judged to be at a higher risk of VTE than any other pregnancy complication studied. No studies were found that measured the risk of pregnancy-related VTE in women with elevated anticardiolipin antibodies, lupus anticoagulants or acquired activated protein C resistance, therefore, the risk of VTE in pregnancy with acquired thrombophilia remains unclear. Furthermore, the risk of DVT and PE could not be established separately as all studies measured VTE as a single outcome.
Of the inherited thrombophilias, only women homozygous for factor V Leiden or heterozygous for prothrombin G20210A had a significant association with early loss. Women homozygous for factor V Leiden or with hyperhomocysteinaemia were at a significantly higher risk of suffering an early pregnancy loss compared to women with other thrombophilias. Moreover, the risk of early pregnancy loss with hyperhomocysteinaemia was greater than the risk of any other pregnancy complication with this condition. The acquired thrombophilias, including elevated anticardiolipin antibodies, lupus anticoagulants and acquired activated protein C resistance, were also significantly associated with pregnancy loss before 24-week gestation. The magnitude of risk was modest; however, early pregnancy loss is a very heterogeneous condition and only a proportion of these losses will be related to thrombophilia. A stronger association was found with recurrent miscarriage, which is likely to be more specific for an underlying thrombophilia. When early pregnancy loss was classified according to recurrent loss in the first trimester and non-recurrent loss in the second trimester, a higher risk of second trimester loss for both factor V Leiden and prothrombin G20210A heterozygotes was calculated. This is consistent with a recent analysis on thrombophilia and recurrent pregnancy loss (Rey et al, 2003) . Although there were insufficient data to ascertain the risk of second trimester pregnancy loss with lupus anticoagulants, the risk of recurrent first trimester pregnancy loss was higher than for any other pregnancy complication with this acquired thrombophilia.
Of all thrombophilias, late pregnancy loss was most strongly associated with protein S deficiency. Women heterozygous for either factor V Leiden or prothrombin G20210A or with lupus anticoagulants were also at significantly increased risk of loss beyond 24-week gestation. The remaining thrombophilias studied were not significantly associated with late loss. These findings are consistent with another systematic review (Alfirevic et al, 2002) , which established that women with protein S deficiency were at the highest risk of unexplained stillbirth after 20 weeks.
Reduced risk
0.001 0.01 0.1 1 10 100 1000 Increased risk * Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia. In comparing early pregnancy loss before 24 weeks and late loss beyond this stage of gestation, we found that in women heterozygous for factor V Leiden or prothrombin G20210A, the risk of late pregnancy loss was higher than that for early loss. These findings are consistent with another systematic review on heritable thrombophilia and fetal loss (Rey et al, 2003) , who also found a significant association between factor V Leiden and fetal loss, the association being more robust if fetal loss arose after 19-week gestation. Our results for acquired thrombophilias indicated that elevated anticardiolipin antibodies and lupus anticardiolipins were associated with higher risk of early pregnancy loss. Studies that did not specify the timing of pregnancy loss were excluded from the review. Data from these studies were pooled together to examine whether including these studies would have influenced the final results. The results from the 12 studies showed that factor V Leiden and prothrombin G20210A were associated with pregnancy loss. Therefore, as these results were obtained before exclusion of these studies, it is unlikely that excluding these studies would influence the final results.
With regard to pre-eclampsia, significant associations with hyperhomocysteinaemia, elevated anticardiolipin antibodies, heterozygosity for factor V Leiden and prothrombin G20210A were found. Pre-eclampsia was the only outcome for which a significant association with homozygosity for MTHFR C677T was found. The increase in risk of pre-eclampsia with thrombophilia is modest. Thrombophilia may contribute to the severity of pre-eclampsia because of an exaggerated effect of the disorder on the haemostatic system in women with thrombophilia (Morrison et al, 2002) . The highest risk of placental abruption was in women heterozygous for prothrombin G20210A, followed by heterozygous factor V Leiden and hyperhomocysteinaemia. These results are similar to those established by other systematic reviews (Gates, 2000; Alfirevic et al, 2002) . In IUGR, the highest risk was in women homozygous for factor V Leiden, followed by heterozygotes for prothrombin G20210A. Alfirevic et al (2002) concluded that pregnant women with elevated anticardiolipin antibodies and protein S deficiency were at highest risk of IUGR. However, their findings were based on only three studies involving very small numbers of women. Additionally, they did not use a prespecified definition of IUGR.
Studies measuring the effectiveness of prophylactic interventions were lacking, in keeping with the findings of the Cochrane review on this area, which included data published up to 2003 (Walker et al, 2005) . It remains to be established whether intervention with LMW heparin is of benefit in women with thrombophilia and an underlying pregnancy complication. Further randomised controlled trials are needed to explore this possibility. Other studies included compared different treatments; therefore, it was not possible to group these studies together. Several studies measured the effectiveness of plaquinil in treating pregnancy-related VTE. This drug is no longer used in clinical practice and as these findings are irrelevant, they were not included in this review. Systematic reviews have several limitations, including selection bias and varying methodological quality of studies. All studies included in this review were independently judged as moderate to high quality using a standardised checklist. Laboratory methods for individual studies used standardised techniques and specific cut-off values to identify thrombophilia. Furthermore, testing for deficiencies of antithrombin, protein C and protein S was performed at least 6 weeks after pregnancy in all studies. Publication bias can arise in systematic reviews. We restricted this review to studies that were published in English. It is well understood that in the field of obstetrics and gynaecology, good quality studies are published in English (Egger et al, 2003) . Therefore, it is believed that excluding non-English studies would make no significant difference to the results.
Due to the fact that not all studies tested for all major thrombophilias, we cannot eliminate the possibility that some control women without the thrombophilia studied were carriers of thrombophilias that were not tested for. This possibility could lead to underestimation of the association between thrombophilia and the adverse outcomes studied. Additionally, it is clear for VTE that individuals from symptomatic thrombophilic kindred differ in risk from unselected individuals or those from asymptomatic kindred with the same thrombophilic genotype. This is likely to be due to an additional (often unidentified) defect or interaction. While this is clear for thrombosis, we have little information of this in pregnancy complications, but it remains likely that the same or similar factors could operate.
Despite strict inclusion criteria, there were instances of interstudy heterogeneity. A possible explanation for such heterogeneity is genetic variations between ethnic populations studied. The studies included in the review were conducted among participants of different ethnic backgrounds. Thrombophilia defects are known to vary according to race, in particular, thrombophilia is more prevalent in Caucasians (Franco et al, 1998; Rosendaal et al, 1998) . This is supported by a study included in this review, where a higher OR was obtained when analysis was restricted to white women only (Dilley et al, 2000) . Another factor that could contribute to the heterogeneous results was different sensitivity and specificity of the laboratory methods used in testing for thrombophilia.
An often overlooked area is the risk of VTE associated with ovarian stimulation for assisted conception therapy, where women are exposed not only to the pregnancy-associated risks of VTE but also the effects of hyperestrogenism. Hyperstimulation is associated with procoagulant changes in the haemostatic and fibrinolytic systems and increased risk of venous and arterial thrombosis, although the overall rate of thrombosis in assisted conception is low (Gompel et al, 2002) . Women with thrombophilia may be at particular risk, and jugular vein thrombosis has been reported following in vitro fertilisation in a compound heterozygote for protein S deficiency and prothrombin G20210A despite therapeutic anticoagulation with a LMW heparin (Reid & Perry, 2001) . Thus, in view of the established risk of VTE with thrombophilia in pregnancy, women with possible thrombophilia undergoing assisted conception therapy require special consideration with regard to their risk of thrombosis and need for prophylaxis.
Conclusions
Recent debate has focused on whether universal screening for thrombophilia should be performed prior to pregnancy. Our review has confirmed that women with thrombophilia are at increased risk of developing complications during pregnancy. However, despite the increase in relative risk, the absolute risk of VTE and adverse outcomes in pregnancy remains low. Furthermore, aside from recurrent pregnancy loss in antiphospholipid syndrome and prevention of VTE, there is insufficient evidence on the benefit of antithrombotic interventions to guide therapy. While there is recent evidence suggesting this possibility in adverse pregnancy outcomes (Brenner et al, 2005) , benefit cannot be concluded in the absence of controlled clinical trials. Such trials are urgently required. Thus, at present, universal screening for thrombophilia in pregnancy cannot be justified clinically.
